SUPPORT tools for evidence-informed health policymaking (STP) 12: Finding and using research evidence about resource use and costs

Health Research Policy and Systems

Volumn 7, Issue SUPPL. 1, 2009, Pages

  Oxman, Andrew D ^a   Fretheim, Atle ^a,b   Lavis, John N ^c   Lewin, Simon ^a,d  

^a NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c MCMASTER UNIVERSITY   (Canada)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; INFORMATION; MEDICAL RESEARCH; MONEY; STAFF;

EID: 73149095390     PISSN: None     EISSN: 14784505     Source Type: Journal    
DOI: 10.1186/1478-4505-7-S1-S12     Document Type: Article

References (27)

1. Lavis JN, Oxman AD, Lewin S, Fretheim A. SUPPORT Tools for evidence-informed health Policymaking (STP). Introduction. Health Res Policy Syst 2009, 7(Suppl 1):I1.
2. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, Vist GE, Schunemann HJ, . GRADE Working Group Incorporating considerations of resources use into grading recommendations. BMJ 2008, 336:1170-3. 10.1136/bmj.39504.506319.80, 2394579, 18497416.
3. Quon BS, Firszt R, Eisenberg MJ. A comparison of brand-name drug prices between Canadian-based Internet pharmacies and major U.S. drug chain pharmacies. Ann Intern Med 2005, 143:397-403.
4. Russell LB. Opportunity costs in modern medicine. Health Aff (Millwood) 1992, 11:162-9. 10.1377/hlthaff.11.2.162, 1500048.
5. Lavis JN, Oxman AD, Grimshaw J, Johansen M, Boyko JA, Lewin S, Fretheim A. SUPPORT Tools for evidence-informed health Policymaking (STP). 7. Finding systematic reviews. Health Res Policy Syst 2009, 7(Suppl 1):S7.
6. Lewin S, Oxman AD, Lavis JN, Fretheim A, García Martí S, Munabi-Babigumira S. SUPPORT Tools for evidence-informed health Policymaking (STP). 11. Finding and using research evidence about local conditions. Health Res Policy Syst 2009, 7(Suppl 1):S11.
7. Oxman AD, Fretheim A, Lavis JN, Lewin S. SUPPORT Tools for evidence-informed health Policymaking (STP). 12. Finding and using research evidence about resource use and costs. Health Res Policy Syst 2009, 7(Suppl 1):S12.
8. Brunetti M, Oxman A, Pregno S, Lord J, Shemilt I, Vale L, Sisk J, Ruiz F, Hill S, Guyatt GH. GRADE guidelines: 10. Special challenges - resource use. J Clin Epidemiol
9. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes 2005, Oxford: Oxford University Press.
10. Luce BR, Manning WG, Siegel JE. Estimating costs in cost-effectiveness analysis. Cost-Effectiveness in Health and Medicine 1996, 176-85. New York: Oxford University Press, Gold MR, Siegel JE, Russell LB, Weinstein MC.
11. Lewin S, Oxman AD, Lavis JN, Fretheim A. SUPPORT Tools for evidence-informed health Policymaking (STP). 8. Deciding how much confidence to place in a systematic review. Health Res Policy Syst 2009, 7(Suppl 1):S8.
12. Simon J, Gray A, Duley L. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG 2006, 113:144-51. 10.1111/j.1471-0528.2005.00785.x, 16411990.
13. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians?. BMJ 2008, 336:995-8. 10.1136/bmj.39490.551019.BE, 2364804, 18456631.
14. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care 2005, 21:240-5.
15. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999, 282:1453-7. 10.1001/jama.282.15.1453, 10535436.
16. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000, 283:2116-21. 10.1001/jama.283.16.2116, 10791503.
17. Palmer S, Raftery J. Economic Notes: opportunity cost. BMJ 1999, 318:1551-2. 1115911, 10356019.
18. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy 2005, 10:245-50. 10.1258/135581905774414187, 16259692.
19. Shemilt I, Mugford M, Byford S, Drummond MF, Eisenstein E, Knapp M, Mallender J, McDaid D, Vale L, Walker D. Chapter 15: Incorporating economics evidence. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008) 2008, The Cochrane Collaboration, Higgins JPT, Green S.
20. Goldhaber-Fiebert JD, Goldie SJ. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc 2006, 4:13. 10.1186/1478-7547-4-13, 1570139, 16887041.
21. Oxman AD, Lavis JN, Fretheim A, Lewin S. SUPPORT Tools for evidence-informed health Policymaking (STP). 16. Using research evidence in balancing the pros and cons of policies. Health Res Policy Syst 2009, 7(Suppl 1):S16.
22. Oxman AD, Lavis JN, Lewin S, Fretheim A. SUPPORT Tools for evidence-informed health Policymaking (STP). 10. Taking equity into consideration when assessing the findings of a systematic review. Health Res Policy Syst 2009, 7(Suppl 1):S10.
23. Oxman AD, Lavis JN, Fretheim A, Lewin S. SUPPORT Tools for evidence-informed health Policymaking (STP). 17. Dealing with insufficient research evidence. Health Res Policy Syst 2009, 7(Suppl 1):S17.
24. Fretheim A, Oxman AD, Lavis JN, Lewin S. SUPPORT Tools for evidence-informed health Policymaking (STP). 18. Planning monitoring and evaluation of policies. Health Res Policy Syst 2009, 7(Suppl 1):S18.
25. O'Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT, Forsetlund L, Bainbridge D, Freemantle N, Davis DA. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007, 4:CD000409.
26. Fretheim A, Oxman AD, Treweek S, Bjorndal A. Rational Prescribing in Primary Care (RaPP-trial). A randomised trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice. BMC Health Serv Res 2003, 3:5. 10.1186/1472-6963-3-5, 152643, 12657163.
27. Fretheim A, Aaserud M, Oxman AD. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice. PLoS Med 2006, 3:e216. 10.1371/journal.pmed.0030216, 1472698, 16737349.